Enoxaparina Rovi 4.000 UI (40 mg)/0

DRUG3 trials

Sponsors

European Foundation For The Study Of Chronic Liver Failure, Unidade Local De Saude De Sao Jose E.P.E., Fundacio Sant Joan De Deu

Conditions

CirrhosisFetal Growth RestrictionVenous malformation or low-flow venous/lymphatic malformation

Phase 2

A novel COMBinATorial therapy with albumin and enoxaparin in patients with decompensated cirrhosis at high-risk of poor outcome (COMBAT trial).

RecruitingCTIS2023-507073-18-00

European Foundation For The Study Of Chronic Liver FailureCirrhosis

Start: 2024-04-24Target: 80Updated: 2025-10-27

Phase 3

Phase III, randomized, open-label, single-site clinical trial to evaluate the efficacy and safety of enoxaparin as a prophylactic treatment for localized intravascular coagulopathy and the impact of endothelial damage markers in patients aged 0 to 18 years with slow-flow vascular malformations undergoing percutaneous interventional procedures (PEaRL-X)

RecruitingCTIS2025-521196-32-00

Fundacio Sant Joan De DeuVenous malformation or low-flow venous/lymphatic malformation

Start: 2025-09-12Target: 60Updated: 2026-01-26

Phase 4

Low molecular weight heparin in the treatment of early fetal growth restriction – a Randomized Controlled Trial

Not yet recruitingCTIS2024-516572-15-00

Unidade Local De Saude De Sao Jose E.P.E.Fetal Growth Restriction

Target: 160Updated: 2024-09-16